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Abbreviation Meaning
aa amino acid
AChR actetylcholine receptor
ADEM acute disseminated encephalomyelitis
AQP4 aquaporin-4
CNS central nervous system
CSF cerebrospinal ﬂuid
CRION chronic relapsing inﬂammatory optic neuritis
DNA deoxyribonucleic acid
EGFP enhanced green ﬂuorescent protein
ELISA enzyme linked immunosorbent assay
FACS ﬂuorescence-activated cell sorting
FCS fetal calf serum
hMOG human MOG
mAb monoclonal antibody
MCF mean channel ﬂuorescence
mMOG mouse MOG
MOG myelin oligodendrocyte glycoprotein
mono ADS patients experiencing only one acquired demyelinating event
MS multiple sclerosis
NMO neuromyelitis optice
ON optic neuritis
PBS phosphate buﬀered saline
PCR polymerase chain reaction
TM transverse myelitis
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5 Abstract
Myelin Oligodendrocyte Glycoprotein (MOG) is one of the few proteins known to be lo-
calized on the outermost sheath of central nervous system (CNS) myelin. Due to this
localization, MOG is accessible to antibodies. Anti-MOG antibodies are demyelinating
and enhance clinical symptoms in a number of animal models of CNS inﬂammation.
Autoantibodies recognizing conformationally intact MOG are found in diﬀerent inﬂam-
matory diseases of the CNS, but their antigenic epitopes had not been mapped. In this
work, 9 variants of MOG with an intracellular enhanced green ﬂuorescent protein (EGFP)
tag were expressed on the cell surface of human HeLa cells and used to analyze sera from
111 patients (104 children, 7 adults), who had antibodies recognizing cell-bound human
MOG. These patients had diﬀerent diseases, namely acute disseminated encephalomyeli-
tis (ADEM), one episode of transverse myelitis or optic neuritis, multiple sclerosis (MS),
anti-aquaporin-4 (AQP4)negative neuromyelitis optica (NMO), and chronic relapsing in-
ﬂammatory optic neuritis (CRION).
The expression levels of the mutants were comparable and cells with a deﬁned ex-
pression level (ﬂuorescence intensity in the EGFP channel of 102-103) were gated. Each
MOG-mutant was recognized by at least one MOG-speciﬁc mAb. This allowed the com-
parison of binding to the diﬀerent mutants. In order to assess the reproducibility of the
system, binding of the 111 sera to the mutants was analyzed up to three times in indepen-
dent experiments, yielding a very good reproducibility of the binding percentage with an
absolute SD of 7.8% in the case of low recognition of a mutant and a relative SD of 20%
in the case of high recognition of a mutant.
The applied variants of MOG gave insight into epitope recognition of 98 patients. All
epitopes identiﬁed in this work were located at loops connecting the ß-strands of MOG. The
immunodominant epitope of human anti-MOG antibodies was at the membrane-proximal
CC'-loop containing aa42, which is not present in rodent MOG. This loop was recognized
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by about half of all patients. Overall, seven epitope patterns were distinguished, including
the one mainly recognized by mouse mAbs at the FG-loop around aa104. Evidence from
mouse models of CNS inﬂammation shows that anti-MOG antibodies recognizing diﬀerent
epitopes can be demyelinating and thus pathogenic. This suggests that not only those
antibodies recognizing the same epitope of MOG as the pathogenic mAbs (i.e. the FG-
loop), but also the ones recognizing the CC'-loop are pathogenic in humans, as both
epitopes allow for the recognition of cell-bound MOG.
In half of the patients, the anti-MOG response was directed to a single epitope. To
analyze the eﬀect of glycosylation on the recognition of MOG by human autoantibodies, a
non-glycosylation mutant N31D was made. Digestion with PNGaseF and Western blot
analysis conﬁrmed that N31 was the only used N-glycosylation site of the MOG constructs
in HeLa cells. Glycosylation of MOG was not needed for antibody binding, but 8% of the
patients recognized deglycosylated MOG at least two-fold better.
The epitope speciﬁcity was not linked to certain disease entities. The individual epitope
recognition patterns stayed constant in 11 analyzed patients over an observation period of
up to 5 years without evidence for intramolecular epitope spreading. Some patients with
acute syndromes had anti-MOG IgG at disease onset, but rapidly lost their anti-MOG IgG
reactivity. These patients were able to generate a long-lasting IgG response to measles and
rubella virus vaccine indicating that the loss of anti-MOG reactivity was not reﬂective of
a lack of capacity for longstanding IgG responses.
Human anti-MOG antibodies are mainly of the IgG1 isotype, which can activate com-
plement and antibody dependent cellular cytotoxicity. Upon binding to MOG in the CNS,
human anti-MOG antibodies are hence expected to cause demyelination. Transfer ex-
periments with puriﬁed human anti-MOG antibodies have not been performed yet. The
fact that the majority of human anti-MOG antibodies did not recognize rodent MOG has
implications for animal studies. Using the described assay will help to identify patient sam-
ples appropriate for these transfer experiments and ﬁnally lead to the formal proof of the
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pathogenicity of human anti-MOG antibodies. This work also gives important information
for future detection of potential mimotopes and the development of anti-MOG antibody
detection assays and might pave the way to antigen-speciﬁc depletion.
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6 Zusammenfassung
Das Myelin Oligodendrozyten Glykoprotein (MOG) ist eines der wenigen Proteine, von
denen bekannt ist, dass sie sich auf der äußersten Schicht der Myelinscheide im zentralen
Nervensystem (ZNS) beﬁnden. Aufgrund dieser Lokalisation ist MOG für Antikörper er-
reichbar. Antikörper gegen MOG wirken in Tiermodellen demyelinisierend und verstärken
dort die klinischen Symptome.
Antikörper gegen konformationelles MOG werden in unterschiedlichen entzündlichen
Erkrankungen des ZNS gefunden, aber ihre antigenen Epitope wurden bisher nicht bes-
timmt. In dieser Arbeit wurden 9 MOG-Varianten mit intrazellulärer EGFP-Markierung
auf der Zelloberﬂäche von HeLa-Zellen exprimiert und verwendet, um Seren von 111 Pa-
tienten (104 Kindern, 7 Erwachsenen) mit Antikörpern gegen zellgebundenes MOG zu
untersuchen. Diese Patienten hatten unterschiedliche Krankheiten, namentlich akute dis-
seminierte Enzephalomyelitis (ADEM), ein Ereignis einer transversen Myelitis oder Sehn-
erventzündung, Multiple Sklerose (MS), anti-Aquaporin-4 negative Neuromyelitis optica
(NMO) und chronisch wiederkehrende Sehnerventzündung (CRION).
Der Expressionslevel der Mutanten war vergleichbar und es wurden Zellen mit einem
deﬁnierten Expressionslevel (Fluoreszenzintensität im EGFP Kanal von 102-103) aus-
gewählt. Jede MOG Variante wurde von mindestens einem monoklonalen Antikörper erkan-
nt. Somit konnte die Erkennung einzelner Mutanten untereinander verglichen werden. Um
die Reproduzierbarkeit dieses Systems zu überprüfen, wurde die Bindung der 111 Seren
zu den Mutanten bis zu dreimal in unabhängigen Experimenten gemessen. Die Ergeb-
nisse waren sehr gut reproduzierbar, mit einer absoluten Standardabweichung von 7.8%
bei geringer Erkennung einer Mutante und einer relativen Standardabweichung von 20%
im Falle guter Erkennung einer Mutante.
Die eingesetzten MOG Varianten gaben Einblick in die Epitoperkennung von 98 Pa-
tienten. Alle in dieser Arbeit identiﬁzierten Epitope beﬁnden sich in den Schlaufen, die
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die ß-Stränge von MOG miteinander verbinden. Das immundominante Epitop humaner
anti-MOG Antikörper lag an der membrannahen CC'-Schlaufe, die die Aminosäure 42 en-
thält, welche in Maus-MOG nicht vorhanden ist. Diese Schlaufe wurde von ungefähr der
Hälfte der Patienten erkannt. Zusammen wurden sieben Epitop-Erkennungsmuster unter-
schieden, inklusive jenem um die FG-Schlaufe mit Aminosäure 104, welches hauptsächlich
von monoklonalen Maus Antikörpern erkannt wird.
In ungefähr der Hälfte der Patienten war die anti-MOG Antwort gegen ein einzelnes Epi-
top gerichtet. Um zu untersuchen, welche Rolle die Glykosylierung in der Erkennung von
MOG durch humane Antikörper hat, wurde die Nicht-Glykosylierungs-Mutante N31D
hergestellt. Verdau mit PNGase F und Western blot Analyse bestätigten, dass N31 die
einzige verwendete N-Glykosylierungsstelle der MOG Konstrukte in HeLa Zellen war.
Glykosylierung war für die Antikörperbindung nicht nötig, aber 8% der Patienten erkan-
nten nicht glykosyliertes MOG mindestens doppelt so gut.
Es gab keine Verbindung zwischen Epitoperkennung und einer bestimmten Krankheit.
Die individuellen Epitop-Erkennungsmuster blieben unverändert in 11 untersuchten Pa-
tienten über einen Beobachtungszeitraum von 5 Jahren, ohne dass es Hinweise auf in-
tramolekulare Epitop-Ausweitungen gab. Einige Patienten mit akuten Erkrankungen hat-
ten anti-MOG Antikörper in der akuten Phase ihrer Krankheit, aber verloren diese rasch.
Diese Patienten konnten dennoch eine nachhaltige IgG Antwort zu einer Masern- und
Rötelnviren Impfung bilden. Dies zeigt, dass der Verlust der anti-MOG Antwort nicht auf
eine generelle Unfähigkeit, nachhaltige IgG Antworten zu bilden, zurückzuführen ist.
Menschliche anti-MOG Antikörper haben hauptsächlich den IgG1 Isotyp, der Kom-
plement aktivieren und Antikörper-abhängige zelluläre Toxizität auslösen kann. Es wird
erwartet, dass anti-MOG Antikörper, wenn sie MOG im ZNS binden, zu Demyelinisierung
führen. Transferexperimente mit aufgereinigten MOG-Antikörpern wurden bisher nicht
durchgeführt. Die Tatsache, dass die Mehrheit der menschlichen anti-MOG Antikörper
Maus-MOG nicht erkannt haben, hat Konsequenzen für Tierstudien. Durch den Einsatz
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des hier beschriebenen Verfahrens können Patientenproben identiﬁziert werden, die sich für
diese Transferexperimente eignen und dies wird letztlich dazu führen, dass die Pathogenität
von MOG-Antikörpern formal bewiesen wird. Diese Arbeit liefert darüber hinaus wichtige
Informationen für die spätere Ermittlung potenzieller Mimotope und die Entwicklung von
anti-MOG Antikörper-Assays und könnte den Weg zu einer Antigen-speziﬁschen Depletion
ebnen.
Part II
Introduction
7 Inﬂammatory diseases of the central nervous system 18
7 Inﬂammatory diseases of the central nervous system
There is a broad spectrum of inﬂammatory diseases of the central nervous system (CNS).
Diseases investigated in this study include multiple sclerosis (MS), monophasic acquired
demyelinating syndromes (mono ADS), acute disseminated encephalomyelitis (ADEM),
Neuromyelits optica (NMO) and Chronic relapsing inﬂammatory optic neuritis (CRION).
An overview over these diseases is shown in ﬁgure 1. Most of the patients in this study are
children, because anti-MOG antibodies are more common in children than in adults (see
12.2). MS is the most common, chronic inﬂammatory disease of the CNS, with a preva-
lence of 60-200/100.000 in Northern Europe and Northern America[Sospedra et al. 2005].
Pediatric MS is rare, accounting for only 3-5% of all MS cases. There are two major forms
of MS: 85-90% of MS-patients show a relapsing-remitting course that usually changes to a
secondary progressive form; 10-15% of the patients show a primary progressive form of MS.
Mono ADS presentations include one episode of optic neuritis (ON), transverse myelitis
(TM) or ADEM [Banwell et al. 2009], but in this work, ADEM will be treated separately.
A proportion of 16-25% of children initially diagnosed with mono ADS, are ﬁnally diagnosed
with MS before turning 18 [Banwell et al. 2009]. ADEM is an acute disorder of the CNS,
which is most common in children younger than 10 years. ADEM is usually monophasic
with a good prognosis. The majority of reported ADEM cases happened in the context
of viral illness or vaccination [Tenembaum et al. 2002]. NMO is a very rare disease with
a prevalence of only 0.5-4.4/100.000 [Jacob et al. 2013]. Importantly, NMO is a lot more
common in Asia [Lennon et al. 2004]. NMO is characterized by recurrent optic neuritis and
longitudinally extended transverse myelitis spanning more than three vertebral segments.
The majority of NMO patients has antibodies against AQP4 [Weinshenker et al. 2006].
CRION is a not well understood condition characterized by recurrent painful inﬂamma-
tion of the optic nerves causing subacute visual loss [Kidd et al. 2003]. CRION patients
respond well to corticosteroid treatment and usually do not have white matter lesions.
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Figure 1: Acquired CNS inﬂammatory demyelinating diseases. This ﬁgure was taken from
[Reindl et al. 2013].
8 Myelin Oligodendrocyte Glycoprotein (MOG)
MOG is a small (218 amino acids) and quantitatively minor component of CNS myelin
(less than 0.05% of all CNS myelin proteins). It is found on the outermost surface of
myelin [Brunner et al. 1989]. Other more abundant myelin components, such as myelin
basic protein, are not found on the surface of CNS myelin and are hence inaccessible for
antibodies. Human MOG has not yet been crystallized, but crystal structures of rat MOG
together with the Fab fragment of the mAb 8-18C5 [Breithaupt et al. 2003] and mouse
MOG [Clements et al. 2003] have been published. MOG features an IgV-like fold (see
ﬁgure 2) with a single glycosylation site N31 [Gardinier et al. 1993]. The exact function
of MOG is not known, but its structure and localization suggest a role as an adhesion
molecule, possibly gluing CNS myelin ﬁbers together [Clements et al. 2003]. MOG itself is
also able to bind the complement component C1q and might therefore regulate the classical
complement pathway [Johns et al. 1997]. MOG might also function as a host cell receptor
for the rubella virus [Cong et al. 2011]. A MOG knockout mouse, however, showed no
obvious phenotype [Delarasse et al. 2003].
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Figure 2: IgV like fold of mMOG. This ﬁgure was taken from [Clements et al. 2003].
9 Autoantibodies in encephalopathies and inﬂamma-
tory CNS diseases
9.1 Autoantibodies contribute to CNS inﬂammation
Autoantibodies are important players in a number of inﬂammatory CNS dis-
eases [Vincent et al. 2011, Lancaster et al. 2012, Iorio et al. 2012, Krumbholz et al. 2012,
Srivastava et al. 2012, Quintana et al. 2008]. Plasma exchange is eﬀective in remov-
ing antibodies from the circulation and is a useful therapy option for a subset of MS
[Keegan et al. 2005, Magana et al. 2011] and NMO patients [Kim et al. 2013]. The suc-
cess of this therapy proves the pathogenic potential of autoantibodies. Transfer studies, in
which human anti-AQP4 antibodies were injected into animals, have proven the pathogenic
potential of these anti-AQP4 antibodies in NMO [Bennett et al. 2009, Bradl et al. 2009,
Saadoun et al. 2010, Kinoshita et al. 2009]. MOG is one of the few proteins known to
be localized on the outermost surface of CNS myelin [Brunner et al. 1989] (see ﬁgure 3).
MOG is hence accessible for pathogenic autoantibodies, as reviewed in [Mayer et al. 2012].
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Figure 3: The position of MOG in CNS myelin. (This ﬁgure was taken from [Mayer et al. 2012],
it was created by the author of this thesis.) A neuron with a myelinated axon is depicted. Myelin
enwraps the axon at intervals called internodes omitting small openings termed nodes of Ranvier.
The zones next to the nodes of Ranvier are the paranode and the juxtaparanode. All four zones
have a characteristic protein composition, as marked in the upper part of the picture. Typical
myelin proteins are found at the internode: Proteolipid protein (PLP) and Myelin basic protein
(MBP) are the major myelin proteins. MOG is a minor component of myelin and one of the few
proteins known to be localized on the surface of the myelin sheath.
10 Treatment of inﬂammatory CNS diseases with therapeutics targeting
B-cells and antibodies 22
9.2 Evidence for a pathogenic role of anti-MOG antibodies in hu-
mans
Anti-MOG antibodies are pathogenic in rodents [Linington et al. 1988,
Schluesener et al. 1987] and primates [Genain et al. 1995]. A pathogenic role of
anti-MOG antibodies in CNS inﬂammation is supported by several observations. First,
anti-MOG antibodies found in subgroups of inﬂammatory diseases recognize cell-bound
MOG (see below). Second, the demyelinating activity of anti-MOG antibodies in
animal models correlates with their ability to ﬁx complement [Piddlesden et al. 1993].
Human anti-MOG antibodies are mostly of the complement activating isotype IgG1
[Proebstel et al. 2011, McLaughlin et al. 2009, Mader et al. 2011]. Antibody-dependent
cellular cytotoxicity activity of human anti-MOG antibodies has also been observed in
vitro and is likely to contribute to the pathogenicity of these antibodies [Brilot et al. 2009].
Third, anti-MOG antibodies require a breached bloodbrain barrier to enter the CNS;
they are not pathogenic in the absence of CNS inﬂammation [Litzenburger et al. 1998]. In
a T-cell-mediated encephalitis, the blood-brain barrier is breached, which is demonstrated
by gadolinium-enhancing lesions in the majority of pediatric MS and ADEM patients
[Poser et al. 2007, Waubant et al. 2009].
10 Treatment of inﬂammatory CNS diseases with ther-
apeutics targeting B-cells and antibodies
A detailed overview about the role of B-cells in the treatment of MS is given in
[Krumbholz et al. 2012]. Figure 4 gives an overview over the possible roles of B-cells in
autoimmune processes. NMO patients beneﬁt from an anti-CD20 treatment with the mono-
clonal antibody (mAb)rituximab [Pellkofer et al. 2011], that depletes CD20+ B-cell lineage
cells in blood, CSF and tissue[Hauser et al. 2008]. In a phase II clinical trial, rituximab
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Figure 4: Possible roles of B-cells in the pathogenesis of inﬂammatory CNS diseases. This ﬁgure
was taken from [Krumbholz et al. 2012].
also showed great success in treating relapsing-remitting MS patients [Hauser et al. 2008].
Another anti-CD20 mAb ocrelizumab was also very eﬀective in a phase II clinical trial
in reducing the number of gadolinium-enhancing lesions, but showed serious side eﬀects
[Kappos et al. 2011]. The eﬀect of these therapeutics on autoantibody levels is unclear, rit-
uximab reduced anti-AQP4 levels in some, but not all NMO patients [Pellkofer et al. 2011].
The anti α4-integrin mAb natalizumab is an approved second-line therapeutic for relapsing-
remitting MS. Natalizumab prevents α4-integrin-mediated adhesion and transmigration
of B cells, T cells, and monocytes from the blood into the CNS [Ransohoﬀ et al. 2012].
The sphingosine-1-phosphate receptor modulator FTY720 is also approved as a second-line
treatment in relapsing-remitting MS. It reduces the immune-cell exit from lymphatic tissue
and also has local eﬀects in the CNS [Aktas et al. 2010]. Acute inﬂammatory diseases like
ADEM and ON, as well as MS relapses are treated with steroids. Steroids have a number
of eﬀects on the immune system, including apoptosis of B-cells [Andrï¾÷au et al. 1998].
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A number of mouse mAbs against MOG are available. The ﬁrst and most prominent one
is 8-18C5 [Linnington et al. 1984]. This mAb was raised against rat cerebellar glycopro-
teins. It cross-reacts with murine and human MOG. This mAb is of the IgG1 isotype.
An additional 13 anti-MOG mAbs were raised against bovine lentil lectin-binding pro-
teins (Y1, Y2, Y4, Y6, Y7, Y8, Y9, Y10 and Y11) or partially puriﬁed bovine MOG
(Z2, Z4, Z8 and Z12) [Piddlesden et al. 1993]. All of these mAbs have the isotype IgG1,
with the exceptions of Z2, Z4, and Z12, which are IgG2a. In this study, the two mAbs
8-18C5 and Y11 were used, as they have been shown to recognize diﬀerent epitopes
[Brehm et al. 1999, Breithaupt et al. 2008]. Both mAbs are pathogenic in experimental
autoimmune encephalitis [Piddlesden et al. 1993].
12 Diﬀerent detection methods for anti-MOG antibod-
ies and contradictory results
12.1 Anti-MOG ELISA studies
Numerous studies have analyzed anti-MOG antibodies in diﬀerent patient groups
[Mayer et al. 2012]. Early studies of anti-MOG antibodies in MS patients used an enzyme-
linked immunosorbent assay (ELISA) to determine the anti-MOG antibody titer in pa-
tients' sera and cerebrospinal ﬂuid (CSF) [Xiao et al. 1991]. Using this technique, anti-
MOG antibodies were detected in the CSF of a subset of MS patients, but also in
the control groups. Later studies analyzed the recognition of MOG peptides: anti-
MOG antibodies were isolated by aﬃnity chromatography to MOG coupled agarose and
the binding of these antibodies to synthetic MOG peptides was assessed in an ELISA
[Haase et al. 2001]. Antibodies from both patients and controls recognized several pep-
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tides and no speciﬁc MS-associated binding pattern was found. Only one out of these
17 MS samples and none of the nine healthy controls also recognized cell-bound MOG
in a ﬂow-cytometry assay [Haase et al. 2001]. This implies that antibodies to MOG pep-
tides are found both in patients and in healthy controls, but only a subset of patients has
antibodies recognizing cell-bound MOG. Evidence from animal models shows that recog-
nition of cell-bound MOG is a prerequisite for the pathogenicity of anti-MOG antibodies
[Brehm et al. 1999, Bï¾÷dingen et al. 2004].
12.2 Studies analyzing antibodies to native MOG
A major breakthrough in the understanding of antibodies to MOG came with a
study analyzing ADEM patients along with adult MS patients [O'Connor et al. 2007].
This study used both cell-bound MOG and a tetramer-based assay radioimmunoas-
say. It showed that a proportion of ADEM patients have high anti-MOG an-
tibody levels, while these antibodies are rare in adult MS and only present at
low levels [O'Connor et al. 2007]. Recent studies used cell-bound MOG assays
to detect and quantify anti-MOG antibodies by FACS or immunocytochemistry
[Brilot et al. 2009, Di Pauli et al. 2011, Lalive et al. 2011, McLaughlin et al. 2009,
Proebstel et al. 2011, Kitley et al. 2012, Mader et al. 2011, Rostasy et al. 2013]. Using
cell-bound MOG assays, anti-MOG antibodies were found in a proportion of chil-
dren with ADEM [Proebstel et al. 2011, Mader et al. 2011, McLaughlin et al. 2009,
Brilot et al. 2009], pediatric MS [Proebstel et al. 2011, McLaughlin et al. 2009,
Lalive et al. 2011, Di Pauli et al. 2011], children with optic neuritis (ON) and chil-
dren with recurrent ON [Rostasy et al. 2012], in a subgroup of anti-AQP4 negative
pediatric and adult NMO patients and patients at high risk of developing NMO
[Kitley et al. 2012, Mader et al. 2011, Rostasy et al. 2013].
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12.3 Stability of anti-MOG antibodies over time
Two studies have analyzed the stability of anti-MOG antibodies over time
[Di Pauli et al. 2011, Proebstel et al. 2011]. A correlation was seen between a decline
in antibody titers and full recovery in ADEM patients [Di Pauli et al. 2011]. All 16
ADEM patients analyzed in a 5-year follow up study, had rapidly declining anti-MOG
antibodies, while anti-MOG antibodies detected in the same study in pediatric MS pa-
tients persisted in six of eight patients with ﬂuctuations and were even shown to increase
[Proebstel et al. 2011], see also ﬁgure 5.
Figure 5: Anti_MOG antibodies decline rapidly in ADEM patients and persist in most pediatric
MS patients. This ﬁgure was taken from [Proebstel et al. 2011].
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13.1 Clinically relevant information gained from epitope mapping
Mapping of antibody epitopes allows precise insight into molecular eﬀects exerted by anti-
bodies and gave important insights into a variety of diﬀerent disorders. In the case of anti-
erythropoietin autoantibodies in HIV-patients, the immunodominant antibody-epitopes
correspond to the part of erythropoietin that is recognized by the erythropoietin receptor,
this might contribute to a dysregulation of erythropoietin and contribute to HIV-related
anemia [Tsiakalos et al. 2011]. In some cases, epitope mapping allowed a diﬀerentiation
between patient groups: patients with inﬂammatory bowel disease and coronary heart dis-
ease have antibodies against heat shock proteins 60 and 65. These antibodies are also
found in healthy controls, but the epitopes diﬀered between the three investigated groups
[Fust et al. 2012].
13.2 Epitope spreading
Autoantibody epitope spreading has been described in the context of a number of autoim-
mune diseases. In an animal model of myasthenia gravis, peptides of the acetylcholine
receptor (AChR) were injected into rabbits, which subsequently produced antibodies not
only against these peptides, but also against other parts of the protein [Vincent et al. 1994].
Antimitochondrial antibodies in Primary biliary cirrhosis patients show intra- and in-
termolecular epitope spreading [Mori et al. 2012]. Intermolecular epitope spreading of
anti-citrullinated protein antibodies is a predictor of progression to rheumatoid arthritis
[Sokolove et al. 2012].
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Autoantibodies to MOG are found in subgroups of diﬀerent disease entities. Before this
project, the epitopes of these antibodies were not known. The objectives of this work
were 1. Deﬁnition of epitopes recognized by human autoantibodies on conformationally
intact MOG expressed on the cell surface. 2. Assessment of the distribution of recognized
epitopes in a single patient- is the autoantibody response in a single patient directed against
an immunodominant epitope or is it broadly distributed? 3. Assessment of a possible
linkage between disease entity and epitope recognition. 4. Analysis of the stability of
epitope patterns in individual patients over years. 5. Evaluation of the general ability of
producing a persisting IgG response in patients with a rapidly declining anti-MOG IgG
response.
Part IV
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15.1 Chemicals and consumables
Chemicals were purchased from Sigma-Aldrich (Munich, Germany) or Merck (Darmstadt,
Germany), unless otherwise speciﬁed below. Consumables like pipette tips centrifuge tubes
were purchased from either Eppendorf (Hamburg, Germany) or BD Falcon (Heidelberg,
Germany). Cell-culture material was obtained from Corning (Wiesbaden, Germany) and
Nunc (Langenselbold, Germany).
15.2 Antibodies
The antibodies for the FACS and Western Blot experiments are summarized in table 1.
Target speciﬁcity source Company Catalogue no. Tag
Anti-human IgG, Fcγ goat Jackson Immuno Research 109-066-098 Biotin
Anti-mouse IgG, Fcγ goaat Jackson Immuno Research 115-066-003 Biotin
Streptavidin Jackson Immuno Research 016-190-084 Dy light 649
Anti-GFP rabbit Research Diagnostics n/a -
Anti-rabbit IgG goat Dianova 111-035-006 HRP
Table 1: Antibodies used in this study
15.3 Patient samples
This study included sera of 111 patients with diﬀerent inﬂammatory CNS diseases and
antibodies to cell-bound MOG: mono ADS, ADEM, MS, NMO, CRION and other relapsing
ADS cases (table 2). Of these, 7 patients were adults (18 or older). 54 of these patients had
been recognized as anti-MOG positive in previous studies, 57 additional patients were newly
identiﬁed as anti-MOG positive using our cell-bound assay with transiently transfected cells
from a cohort of 188 pediatric patients with inﬂammatory CNS diseases. The proportion of
sera identiﬁed as positive in this cohort was: ADEM 41%, MS 5%, mono ADS 29%, other
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relapsing cases 80%, CRION 100%. This study was approved by local ethical committees,
and informed consent was obtained from all patients, parents, or legal guardians.
Disease Number of patients with
antibodies to hMOG
(adults)
Number
females
Age mean in
years (range)
Mono ADS other
than ADEM
45 (2) 25 11.0 (1.5-51.8)
ADEM 40 (1) 19 7.0 (1.4-47.1)
MS 10 (1) 7 11.3 (3.4-34)
NMO like 2 (1) 1 34.7 (13.5-55.9)
CRION 10 (2) 6 15.3 (7.4-32)
Other relapsing
ADS
4 1 7.9 (3.2-15.7)
Table 2: Patient data. Other relapsing ADS cases: three patients had one ADEM attack plus one
non- ADEM attack, and one patient had a monolesional transverse myelitis.
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16.1 Determination of putative epitopes
The tip of the FG-loop of MOG is recognized by the mAb 8-18C5 . Hence the two amino
acids H103 and S104 were mutated to obtain H103A/S104E. The single amino acid mu-
tant S104E was also mutated, since this mutant already reduced binding of rMOG to
mAb 8-18C5 by >40% . MOG is glycosylated at N31. In order to analyze the contribu-
tion of the glycosylation for antibody recognition, N31D was chosen as an unglycosylated
MOG-mutant. Because recognition of mMOG was dramatically reduced in the majority
of patients, three mutants of hMOG with the corresponding murine amino acids were cho-
sen (see ﬁgure 6). Dr. Constanze Breithaupt helped with the analysis of the diﬀerences
between human and murine amino acids. The chosen mutations were very surface exposed
in the structure of mMOG and non-conservatively substituted in the sequence of hMOG:
P42S, R9G/H10Y and R86Q.
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Figure 6: Protein sequence alignment of the Ig-V like domain of human MOG (hMOG) and of
murine MOG (mMOG) This ﬁgure was taken from [Mayer et al. 2013] and was prepared by Dr.
Constanze Breithaupt. The amino acid residues are highlighted in color reﬂecting the sequence
conservation of hMOG and mMOG along the spectrum (white indicates identical residues; blue,
purple and red indicate least conservative substitutions). The glycosylation site Asn31 is shown in
green. Below the alignment, the secondary structure elements of mMOG are shown. The arrows
labeled A to G represent the strands of the β-sheet. The green strands represent the front side and
the blue strands the back side of the protein. The FG-loop and neighboring residues representing
the center of the epitope on rat MOG (rMOG) recognized by mAb 8-18C5 are marked by black
circles. Residues which have been mutated in this study are marked with a red circle.
16.2 Molecular cloning
16.2.1 PCR ampliﬁcation of hMOG and mMOG from template vectors
Full length hMOG and mMOG were subcloned into the pEGFP-N1 plasmid (CLONTECH
Laboratories, Inc., Mountain View, USA) in order to make MOG-EGFP fusion proteins,
with the EGFP being at the C-terminus of MOG (see ﬁgure 7).
The primers were manufactured by Metabion (Martinsried, Germany) and are listed in
table 3. The templates used were hMOG in RSV5'neo and mMOG in pLXSN. To amplify
the DNA inserts from the templates, a PCR reaction was performed using the reagents
shown in table 4. All reagents were mixed and a PCR was performed using the program
shown in table 5. The PCR product was puriﬁed using the Qiagen PCR puriﬁcation kit
(Qiagen, Hilden, Germany). The DNA was eluted in 30 μL EB buﬀer (Qiagen).
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Name Description Sequence
CM3 hMOG forward, with XhoI
restriction site
5'-GGC TGC AGC TCG AGA
TGG C-3'
CM4 hMOG reverse, with
EcoRI restriction site
5'-TGT CTG GGA ATT CGG
AAG GGA TTT CG-3'
CM5 mMOG forward, with
XhoI restriction site
5'-CGG TAA CCC TCG AGA
TGG CCT GTT TGT-3'
CM6 mMOG reverse, with
EcoRI restriction site
5'-CAC AAC CAG AAT TCG
AAA GGG GTT TCT-3'
Table 3: Primers used for ampliﬁcation of hMOG and mMOG
Reagent Volume used Stock concentration of reagent
DNA template 5 μL 10 pg/μL
dNTPs 1 μL 2 mM
Taq polymerase 0.5 μL 5 U/μL
Forward primer 2 μL 10 μM
Reverse primer 2 μL 10 μM
Taq buﬀer 5 μL 10x
Water 24.5 μL
Table 4: Reagents for the PCR reaction
Stage Temperature Time
Denaturation 94 3 minutes
Denaturation 94 30 seconds
30 repeatsAnnealing 56 30 seconds
Extension 72 1 minute
Extension 72 10 minutes
Cooling 4
Table 5: PCR program
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Figure 7: Model of a MOG-EGFP fusion protein in a cell. The MOG-model was
taken from [Breithaupt et al. 2008]. The membrane topology was modeled according to
[Della Gaspera et al. 1998]. This demonstrates that the EGFP-tag is intracellular at the C-
terminus of MOG.
16.2.2 Cloning of PCR products into pEGFP-N1 plasmid
The puriﬁed PCR products and the pEGFP-N1 plasmid (ﬁgure 8) were digested with the
restriction enzymes XhoI and EcoRI. For this reaction, 1 μg vector or the entire puriﬁed
PCR product were added to the digestion mix containing 1 μL XhoI, 1 μL EcoRI, 0.1 μg
bovine serum albumine and 1x reaction buﬀer 4 (New England Biolabs, Ipswich, USA).
The digestion was performed at 37 for 1h. The digested DNA was then gel puriﬁed.
16.2.3 Gel puriﬁcation
In order to purify DNA of a desired size from a gel containing multiple DNA fragments,
the gel was exposed to low intensity (312 nm) UV light and the desired fragment was cut
out using a scalpel. The DNA was then puriﬁed from the gel using the QIAquick Gel
Extraction Kit (Qiagen), according to the manufacturer's protocol.
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Figure 8: Vector pEGFP-N1 (picture taken from http://www.human.cornell.edu)
16.2.4 Ligation
Digested and puriﬁed pEGFP-N1 and PCR products were ligated using T4 DNA ligase. To
this end, 50 ng of the digested vector and insert in diﬀerent molar ratios (usually 1:5) were
added to a ligation mix. The ligation mix consisted of 1 μL T4 DNA ligase (Invitrogen)
and 1x T4 DNA ligase buﬀer (Invitrogen). The ligation reaction was performed at 16 for
1h. The reaction was stopped by a heat inactivation of the ligase at 65 for 15 minutes.
16.2.5 Transformation of E. coli DH5α
A 10μL aliquot of the ligated DNA was added to a 50μL aliquot of competent E. coli
DH5α cells. This mixture was incubated on ice for 20 minutes. A heatshock reaction was
performed for 90 seconds at 42. The reaction mix was kept on ice for 4 minutes and 450
μL LB medium were added. The transformed cells were incubated in a shaker at 37 for
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45 minutes to allow for regeneration. The complete reaction was plated onto LB plates
containing 30 mg/mL Kanamycin. The plates were incubated overnight at 37.
16.2.6 Bacterial culture
A single transformed E. coli DH5α cell was picked and added to LB medium containing 30
mg/mL kanamycin. Bacteria were grown while shaking at 37 overnight. For minipreps,
2 mL were inoculated and for maxipreps 100 mL.
16.2.7 Plasmid preparation
Plasmids were prepared from overnight cultures using the Qiaspin Plasmid Miniprep kit
(Qiagen) or the Qiaspin Plasmid Maxiprep Kit (Qiagen). To conﬁrm the correct size of
the puriﬁed DNA and the presence of an insert, a small amount of DNA, usually 200 ng,
was digested with restriction enzymes and analyzed on an agarose gel.
16.2.8 Mutagenesis
Using the QuikChange Site-Directed Mutagenesis kit (Stratagene, Santa Clara, USA),
point mutations were introduced into hMOG using the primers shown in table 6 and the
corresponding reverse complement primers. In the case of the P42S/H103A/S104E mutant,
the P42S mutation was introduced into the H103A/S104E mutant.
16.2.9 DNA sequencing
The DNA was sequenced in order to exclude PCR-generated errors at the MPI of Bio-
chemistry and the LMU Biocenter (both in Martinsried, Germany).
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Mutation Sequence forward primer
S104E 5'-CCT GCT TCT TCC GAG ATC ATG AAT ACC
AAG AGG AGG C-3'
H103A/S104E 5'-CCT GCT TCT TCC GAG ATG CTG AAT ACC
AAG AGG AGG CAG-3'
N31D 5'-CAT ATC TCC TGG GAA GGA CGC TAC AGG
CAT GGA GG-3'
R9G/H10Y 5'-CAG AGT GAT AGG ACC AGG ATA CCC TAT
CCG GGC TCT GG-3'
R86Q 5'-GGT GAC TCT CAG GAT CCA GAA TGT AAG
GTT CTC AGA TG-3'
P42S and
P42S/H103A/S104E
5'-GTG GGG TGG TAC CGC TCC CCC TTC TCT
AG-3'
P42S (Innsbruck) 5'-GTG GGG TGG TAC AGA TCT CCC TTC TCT
AGG-3'
Table 6: Primers used for th QuikChange protocol
16.3 Cell culture of HeLa cells
HeLa cells were cultured in Dulbecco's Modiﬁed Eagle's Medium (DMEM) (Invitrogen)
containing 10% fetal calf serum (FCS) (Gibco) and 1% Penicillin/Streptomycin solution
(Gibco). The cells were cultured in T75 tissue culture ﬂasks (BD Biosciences ) at 37 and
10% CO2 and split 1:2 every 2-3 days. To this end, cells were washed once with phosphate-
buﬀered saline (PBS) (Invitrogen) and trypsinized for about 5 minutes at 37 with 2 mL
trypsin-EDTA (Invitrogen). Trypsinization was stopped by the addition of 10mL complete
medium.
16.4 Transfection of HeLa cells
HeLa cells were transiently transfected with using Metafectene transfection reagent (Bion-
tex, Martinsried, Germany). On the day of transfection, cells were usually 90% conﬂuent.
The cells were trypsinized and suspended in 20 mL fresh complete medium. Subsequently,
the cells were pelleted at 1200 rpm and resuspended in 40 mL complete medium. Per
60mmØ dish, 4.5mL cell suspension were plated. The cells were kept at 37 and 10%
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CO2for no longer than 30 minutes. During this time, the transfection mix was prepared
for every well. In one tube, 7.5 µg DNA were added to 250 µL PBS. In a second tube, 60
µL Metafectene was added to 250 µL PBS. The content of the ﬁrst tube was then added
to the second tube and this mixture was incubated at room temperature for 15 minutes.
After this incubation time, the transfection mix was added to cell dishes. The cells were
incubated at 37 and 10% CO2overnight.
16.5 Flow cytometric analysis of antibody binding
HeLa cells transiently transfected with EGFP only, hMOG-EGFP, mMOG-EGFP and
mutants of hMOG-EGFP were assessed for their recognition by human sera. To this end,
transiently transfected HeLa cells were washed with PBS and trypsinized. After suspension
in complete medium, the cells were pelleted and resuspended in FACS buﬀer (1% fetal calf
serum in phosphate-buﬀered saline). In a 96-well plate, 100,000 cells were incubated with
a 1:50 serum dilution for 45 minutes at 4°C and washed 3 times in FACS buﬀer. The
cells were then incubated with a 1:500 dilution of a biotin-SP conjugated goat anti-human
IgG (Jackson ImmunoResearch) for 30 minutes at 4°C, washed 3 times and incubated with
streptavidin-Dy light 649 (Jackson ImmunoResearch) at a dilution of 1:3000). Finally,
the cells were washed 3 times and suspended in a 1:500 dilution of propidium iodide in
PBS. The stained cells were analyzed using a BD FACSCalibur ﬂow cytometer. Dead
cells were excluded by positive propidium iodide staining. For binding analysis, the cells
showing a 100-fold higher FL-1 ﬂuorescence intensity as the untransfected cells were gated
(expression level FL-1 102-103) and the mean channel ﬂuorescence (MCF) in the FL-4
channel was obtained for these cells. Cells transfected with the mutants, hMOG and with
EGFP only were always measured together in the same experiment in order to determine
the binding percentage as %binding = MCF (mutant)−MCF (EGFP−only)
MCF (hMOG)−MCF (EGFP−only) . In addition, two sera
(adult ADEM patient 18078 and TM patient AEB-123) were serially diluted in FACS
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buﬀer up to a dilution of 1/12800 and the dilutions were used to perform the FACS assay
as described above, in order to show that the binding patterns stay constant at higher
dilutions.
16.6 Competition assay
For competition of the human antibodies, the anti-MOG mAbs 8-18C5 and Y11 were added
to the 1:50 serum dilution at 240ng/well and the transfectants were incubated with the
mixture of serum and mAbs and developed with a 1:500 dilution of biotin-SP conjugated
goat anti-human IgG (Jackson ImmunoResearch) and streptavidin-Dy light 649 1:3000
(Jackson ImmunoResearch) as described above. This anti-human secondary Ab did not
cross-react with the murine mAbs (data not shown).
16.7 Preparation of cell lysates and deglycosylation by PNGase F
In order to analyze the glycosylation of the diﬀerent MOG-EGFP constructs, HeLa cells
were transiently transfected with MOG-EGFP constructs, as described above. The cells
from a 12-well plate well were suspended in 1 mL PBS then pelleted at 13,000 rpm for
2 minutes in a bench top centrifuge. The pellets were washed in 1 mL cold PBS and
pelleted again. The cells were then lysed at 4°C for 1h in 80 µL RIPA buﬀer (150 mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 50 mM Tris pH8, 0.1% SDS) containing
complete protease inhibitor cocktail (Roche Applied Science, Penzberg, Germany). The
lysate was then pelleted at 13,000 rpm for 10 minutes and the supernatant was analyzed.
For deglycosylation, the supernatant was digested with PNGaseF (New England Biolabs) in
Glycoprotein Denaturing Buﬀer (New England Biolabs), G7 Reaction Buﬀer (New England
Biolabs) and 1% NP40 (New England Biolabs) at 37°C overnight.
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16.7.1 SDS PAGE
The total protein concentration of the lysates was determined using a BCA protein assay
reagent kit (Pierce, Rockford, USA) according to the instructions of the manufacturer.
6 µg protein (digested or undigested) was loaded onto an precast 4-12% Bis-Tris gels
(Invitrogen) and separated by gel electrophoresis at 200V for 90 minutes.
16.8 Western blot
The proteins were electro-blotted onto a nitrocellulose membrane at 100mA for 90 minutes.
The membrane was blocked on PBS containing 3% BSA overnight. The membrane was
incubated with a rabbit anti-GFP mAb (Research Diagnostics Inc., Flanders NJ, USA) at
a dilution of 1:5000 for 1h at room temperature, washed three times and then incubated
with a peroxidase-labeled goat anti-rabbit Ab (Dianova, Hamburg, Germany) at a dilution
of 1:10,000 for 1h at room temperature. The blots were developed with enhanced chemilu-
minescence (ECL). The ECL solution consisted of 10 mL ECL-A (0.25% (w/v) luminol in
1M Tris/HCl), 100 μL ECL-B (0.11% (w/v) para-hydroxycoumarin acid in DMSO), and
3.1 μL of 30% H2O2. Luminescence was documented using an autoradiography ﬁlm (GE
Healthcare).
16.9 IgG response to vaccines
The IgG responses to measles and rubella virus were measured by routine ELISA in the
department of clinical chemistry of the LMU using the Enzygnost Anti-Rubella Measles
Virus/IgG and Anti-Measles Virus/IgG assays (Siemens Healthcare, Erlangen, Germany).
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Parts of the following results were published in [Mayer et al. 2013].
17 Cloning and expression of MOG constructs with a
C-terminal, intracellular EGFP tag
hMOG and mMOG were cloned into the pEGFP-N1 plasmid, yielding MOG constructs
with a C-terminal EGFP tag. The hMOG-EGFP construct was then mutated as de-
scribed in Material and Methods to achieve 7 mutants of hMOG with a C-terminal,
intracellular, EGFP-tag (N31D, H103A/S104E, S104E, P42S, R86Q, R9G/H10Y and
P42S/H103A/S104E). Similar extents of expression were obtained with the diﬀerent con-
structs, as shown by comparable FL-1 intensities, reﬂecting EGFP-ﬂuorescence (ﬁgure 9).
Figure 9: Expression intensity of the applied MOG variants. HeLa cells were transiently trans-
fected with the indicated MOG-variant fused to EGFP. Depicted is the ﬂuorescence intensity
of the FL-1 channel (EGFP) of 8 diﬀerent MOG mutants, measured 24h after transfection. Fre-
quency and ﬂuorescence intensity were comparable, allowing for comparison of binding to diﬀerent
mutants. The single mutant S104E is not shown in this ﬁgure, as this mutant was only tested for
a subset of sera, as explained in section 20.1.
Surface expression of each MOG variant was evaluated with two anti-MOG mAbs, 8-
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18C5 and Y11. These two mAbs were chosen because they recognize diﬀerent epitopes
on MOG [Breithaupt et al. 2008]. 8-18C5 did not recognize the three MOG variants con-
taining the S104E mutation, but bound well to all other mutants. All MOG variants were
recognized by Y11(ﬁgure 10).
Figure 10: hMOG and all mutants were recognized equally by the anti-MOG mAb Y11 proving
that they are correctly folded and expressed on the cell surface. In accordance with published data
(Breithaupt et al., 2008) the mAb 8-18C5 does not recognize MOG anymore when the mutation
S104E is introduced.
This shows that the introduced mutations did not interfere with MOG surface expres-
sion. Further it was previously shown that the introduction of the H103A/S104E mutation
did not disturb the overall structure of rat MOG [Breithaupt et al. 2008]. The P42S mu-
tation is also unlikely to change the overall structure of MOG, as both proline and serine
are found in diﬀerent species at this position.
18 Validation of transiently transfected MOG variants and reproducibility of
binding ratios 45
18 Validation of transiently transfected MOG variants
and reproducibility of binding ratios
In order to quantify the recognition of MOG-EGFP mutants by human antibodies, it was
important to ensure 1. comparability of expression levels between the MOG constructs
and 2. reproducibility of the results between diﬀerent experiments. Using MOG-EGFP
fusion proteins allows for comparison of the expression levels. EGFP ﬂuorescence is seen
in the FL1 channel. Cells with the FL1 ﬂuorescence intensity of 102-103 (ﬁgure 11) were
gated to evaluate the binding to the respective transfected cell. This range was selected to
ensure a high expression level and a good comparability between the transfectants. The
calculation of the binding percentage is described in Material and Methods and in ﬁgure
11.
Figure 11: Processing of FACS data to calculate speciﬁc binding. Three diﬀerent transfectants
were stained with the same serum AEB085. Left: HeLa cells transfected with EGFP only (MCF
FL-4= 4.47). Middle: HeLa cells transfected with hMOG- EGFP (MCF FL-4=79.7). Right:
HeLa cells transfected with mMOG-EGFP (MCF FL-4=3.34). For binding calculation gates were
set on the cells with an EGFP expression level between of 102 and 103. Calculation of the binding
percentage for the serum AEB085 shown above: AEB085 % binding of mMOG compared to
hMOG= (3.34−4.47)(79.7−4.47) × 100% = −1.5%≈0%.
The similar expression levels of the mutants, the gating on cells with a deﬁned ex-
pression level (102-103), and the demonstration of binding of at least one MOG-speciﬁc
mAb allowed the comparison of binding to the diﬀerent mutants. In order to assess the
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reproducibility of the system, binding of the 111 sera to the mutants was analyzed up to
three times in independent experiments, yielding a very good reproducibility of the binding
percentage: For 36 sera, recognition of the three most important constructs P42S, mMOG
and H103A/S104E to hMOG (i.e. 108 measurements and each in triplicates) was analyzed,
yielding following results: A) In 33/108 measurements the mutation reduced the binding
to less than 10%, with an absolute SD of 7.8%. B) In the other 75 measurements, binding
was either strongly reduced (i.e. below 65%), comparable to hMOG (i.e. between 65 and
200%) or strongly increased (i.e. above 200%); here the SD of the binding was 20% of the
binding percentage. Representative sera analyzed three times are shown in ﬁgure 15. A
subset of 16 sera was independently analyzed by Prof. Dr. Markus Reindl in Innsbruck for
binding to P42S and mMOG by titration in an immunoﬂuorescence assay using transiently
transfected HEK-293A cells: the resulting 32 binding percentage values were very well
comparable between the independent assays: Spearman r=0.7136, p<0.0001. This shows
that the results are even reproducible in a diﬀerent experimental setup.
19 Glycosylation of MOG-EGFP fusion proteins in
HeLa cells
HeLa cells were transiently transfected with the diﬀerent MOG-EGFP constructs, the
lysates were digested with PNGaseF and the size of the digested and undigested fusion
proteins were compared with a Western-blot in order to assess their N-glycosylation. Deg-
lycosylation with PNGaseF yielded MOG-EGFP fusion proteins with the same size as the
N31D mutant (ﬁgure 12), indicating that N31D is the only N-glycosylation site used in
this setting.
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Figure 12: N31D mutation completely abrogates MOG-glycosylation. Cell lysates of HeLa cells
transiently transfected with MOG-variants were digested with PNGase F as indicated; 6 mg total
protein were loaded into each well of an SDS gel, separated by gel electrophoresis, blotted onto
nitrocellulose, incubated with a rabbit anti-EGFP mAb and developed with a peroxidase-labeled
goat anti-rabbit antibody and ECL. After digestion with PNGase F, all MOG-mutants had the
same size as N31D. Digestion of N31D did not alter the size of this particular mutant.
20 Recognition of MOG-epitopes analyzed with single
and multiple amino acid mutants
98/111 anti-MOG positive sera showed a reduced binding to at least one of the MOG
variants. In 52/111 samples, the immune response was clearly reduced by mutations of
amino acids positioned in only one loop. In 39/52 patients, binding to single mutated
loops was decreased to less than one third, indicating that the IgG response is focused on
one epitope. In 32/111, binding to multiple mutants was reduced and in 14/111 samples
there was no binding to mMOG, but no speciﬁc responsible amino acid was identiﬁed.
The responses to the described mutants allowed distinction of 7 diﬀerent patterns of MOG
recognition. The intensity of the recognition of hMOG did not diﬀer signiﬁcantly between
sera recognizing the 7 patterns, as summarized in ﬁgure 14. The structure of MOG with
the strands and loops referred to in this work is shown in ﬁgure 13. An overview of these
patterns is shown in ﬁgure 14 and examples of the seven patterns are shown in ﬁgure 15.
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Figure 13: Structure of MOG and modeling of the epitopes recognized by human autoantibodies
on MOG. This ﬁgure was taken from [Mayer et al. 2013] and was created by Dr. Constanze
Breithaupt. MOG has an IgV like fold, which means it looks a bit like a sandwich formed by two
slices of toast. The toast slices are called β-sheets (one is shown in green, the other one is blue),
they are both made up of amino acid chains. These chains (called β-strands) run antiparallel
to each other. The β-strands are connected to each other by loops, which also consist of amino
acids. Residues at positions that were mutated in this study are shown as a stick model. Close-
up views of these regions show the superposition of the side chains of hMOG (gray) modeled
with SWISS-MODEL [Schwede et al. 2003] and the corresponding side chains of mMOG, the
rMOG double mutant H103A/S104E [Breithaupt et al. 2008] and the modeled N31D mutation,
respectively (orange).
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Figure 14: Anti-MOG reactivity grouped in seven patterns. The epitope recognition of 111 sera
was analyzed using 9 MOG variants. Epitope patterns were assigned in 98 samples, which were
grouped into seven patterns, indicated by the numbers 17 in row 4. Fifty-two of 98 samples
showed an immune response focused on one epitope (patterns 13). Fourteen of 98 samples
showed reduced binding to mMOG, but recognized all other mutants well (pattern 4). Thirty-two
samples showed an immune response directed against multiple distant epitopes (patterns 57). In
the last row, the intensity of the anti-hMOG reactivity of each pattern is indicated. The values
shown are the FACS ratios (MCF reactivity to hMOG/MCF reactivity to EGFP; mean ± SEM).
The anti-hMOG reactivity varied within each pattern, but did not diﬀer signiﬁcantly between the
diﬀerent patterns (diﬀerence between any two patterns, one-way ANOVA, p >0.05).
20 Recognition of MOG-epitopes analyzed with single and multiple amino
acid mutants 50
Figure 15: Examples of the seven identiﬁed epitope patterns of anti-MOG reactivity. Depicted
is the mean percentage binding value of three independent experiments. Error bars represent the
SD. In patterns 13 the anti-MOG IgG response is focused on only one epitope. In pattern 1, the
anti-MOG response is directed against the CC'-loop of MOG, binding to P42S and to mMOG is
reduced; binding to P42S/H103A/ S104E is also reduced. In pattern 2, the anti-MOG response
is directed against the FG-loop of MOG; this causes a reduction in binding to H103A/S104E and
to P42S/H103A/S104E. In pattern 3, the anti-MOG response is directed against the EF-loop of
MOG. Binding to R86Q and to mMOG is reduced. In pattern 4, binding to mMOG is reduced, but
the mutations P42S, R86Q, and R9G/H10Y introducing individually the murine amino acids had
no eﬀect on binding. The immune response of patients recognizing patterns 57 is directed against
multiple distinct epitopes. In pattern 5, the anti-MOG response is directed against the FG-loop
and the CC'-loop of MOG. Binding to H103A/S104E, P42S/ H103A/S104E, mMOG, and P42S is
reduced. In pattern 6, binding to H103A/S104E and to mMOG is reduced; the mutations P42S,
R86Q, and R9G/H10Y had no eﬀect on binding. In pattern 7, binding was directed against the
CC'- loop (reduced binding to P42S) and to a second loop, either the EF-loop (reduced binding
to R86Q) or the AA'-loop (reduced binding to R9G/H10Y).
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20.1 Patients with anti-MOG IgG directed to one epitope
The most frequently recognized MOG-epitope was revealed by the P42S mutation posi-
tioned in the CC'-loop (ﬁgure 6). 66/111 patients (59%) showed a reduced or no binding to
this mutant (patterns 1, 5 and 7). Moreover, in 41/111 patients (37%) the MOG-speciﬁc
Ab response was focused on the CC'-loop (pattern 1, ﬁgure 15A). 36 of these 41 sera also
showed reduced or no binding to mMOG, which was expected, since mMOG contains S42.
In 21 of these 36 cases, binding to mMOG was lower than binding to P42S indicating that
other diﬀerences between human and murine MOG further decreased binding to mMOG.
The CC'-loop is hence identiﬁed as the most frequently recognized epitope on hMOG and
as the dominant epitope in patient sera recognizing a single epitope. The tip of the FG-loop
(which is the main target of anti-MOG mAbs) is recognized by 36/111 (32%) patients. In
a subgroup of 10 patients (9%) the immune response is strongly focused on this region
(pattern 2, ﬁgure 15B). These sera showed reduced or no binding to the double mutant
H103A/S104E but bound well to the other mutants (P42S, R9G/H10Y, R86Q, N31D and
mMOG). Comparing the reactivity of these 10 sera to the single mutant S104E and to
the double mutant H103A/S104E revealed heterogeneity in recognition of the FG-loop: In
8/10 sera, reduced recognition of both the single mutant S104E and the double mutant
was reduced, reminiscent of the binding pattern of the mAb 8-18C5. However, one other
serum showed no decrease in binding to S104E, whereas one serum showed strongly in-
creased binding to S104E, but not to H103A/S104E (data not shown). To analyze whether
binding to the double mutant H103A/S104E and the single mutant S104E was compara-
ble, 76 sera were measured with both mutants. These sera showed either decreased (34
sera binding less than 65%) or good recognition (42 sera) of H103A/S104E. Recognition
of these two mutants was very similar (ﬁgure 16). This ﬁgure shows also that some sera
bind better to these mutants than to the hMOG.
One serum did not bind the R86Q mutant anymore (pattern 3, ﬁgure 15C) and hence
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Figure 16: Binding to the double mutant H103A/S104E in comparison to the single mutant S104E.
Binding to H103A/S104E was decreased (to less than 65%) in 34 of all sera. For these 34 and
additional 42 sera binding well to H103A/S104E (76 in total) recognition of the single mutant
S104E was also assessed. Depicted are the binding percentages for the 76 sera. Sera with low
reactivity to hMOG (FACS ratio below 2.0) are depicted as open circles. The correlation was
highly signiﬁcant (Spearman r= 0.85, p<0.0001). One ON patient recognized S104E with 1506%
binding, but did not recognize the double mutant H103A/S104E.
recognized the EF-loop of MOG (ﬁgure 6). This serum also did not bind mMOG, as ex-
pected, since mMOG contains Q86. This serum recognized all other mutants well. For
14/111, we found a reduced recognition of mMOG, but were not able to identify the pre-
cise recognized epitopes (pattern 4, ﬁgure 15D). These anti-MOG antibodies might target
regions with rather conservative mutations (C''D-loop or DE-loop, see ﬁgure 6) or their
binding might be inﬂuenced by subtle structural diﬀerences that cannot be mimicked by
the chosen mutants. In summary, the immune response was directed against one single epi-
tope in 52/111 sera. The most frequently found single epitope is dominated by P42 that is
not found in mMOG. The major mAb epitope located at the FG-loop is conserved between
mMOG and hMOG and is the second most frequently recognized epitope in humans.
20.2 Patients with anti MOG IgG recognizing multiple epitopes
Reduced binding to multiple mutants was observed in 32/111 (29%) patient samples. The
most common combination, present in 19 of 32 samples, was reduced binding to P42S and
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to H103A/S104E (pattern 5, ﬁgure 15E). These mutations are located in loops at oppo-
site ends of the A'GFCC'C'' β-sheet of MOG. The average distance of the Cα atoms was
determined by Dr. Constanze Breithaupt as distance of Cα atoms: daverage= 23Å). The
observed maximum dimensions of Ab epitopes are 21Å x 28Å [Ramaraj et al. 2012]. As
exempliﬁed by the MOG Igd (8-18C5) Fab complex structure in which the FG-loop forms
the center of the epitope whereas S42 is located too far away to interact with antibody
amino acids, P42 and H103/S104 cannot simultaneously bind to the center of an antibody
paratope. Indeed, in 64/111 (58%) patient samples antibodies recognize either P42 (pat-
tern 1, 7) or H103/S104 (pattern 2, 6). For this reason, sera showing pattern 5 reactivity
can be assumed to contain at least two diﬀerent antibody populations recognizing distinct
epitopes. 4 of these 19 samples, however, showed strongly reduced binding (<10%) to
both H103A/S104E and to P42S. This indicates that in these sera both loops inﬂuence
antibody binding simultaneously. Considering the observed maximum dimensions of anti-
body epitopes and the distance between the two MOG loops, the epitopes recognized by
these samples have to be very extended with hot spots of binding in the two loops at the
edges of the epitope. In 7/111 patient samples, binding to H103A/S104E and to mMOG
was reduced or abolished, but recognition of P42S and R9G/H10Y and R86Q was good
(pattern 6, ﬁgure 15F). In 6/111 samples, binding was reduced to the P42S mutant and to
the R9G/H10Y or to the R86Q mutant (pattern 7, ﬁgure 15G). We noted that sera show-
ing pattern 7 reactivity, diﬀer in reactivity to mMOG (binding to mMOG was reduced
in 4/6) indicating that within this pattern further epitopes are recognized to diﬀerent ex-
tends. Taken together, a subset of 32/111 sera showed reduced reactivity to various MOG
constructs carrying distant mutations. In paragraph 20.1 it was described that the most
frequently recognized epitopes are found at the CC'-loop and at the FG-loop of hMOG.
In addition, the reactivity to both of these two epitopes is the most common combination
among sera recognizing multiple epitopes.
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20.3 The triple mutant P42S/H103A/S104E
Binding to the triple mutant P42S/H103A/S104E, which combined the two most important
epitopes of human anti-MOG IgG, was reduced in 64% of all sera. As expected, all 19 sera
that showed a reduced binding to both P42S and H103A/S104E showed strongly decreased
binding to the triple mutant (less than 35% binding) (pattern 5, ﬁgure 15E). Within the
group of 41 samples that recognized the immunodominant P42 (pattern 1), 13 showed
increased, i.e. more than 200%, binding to H103A/S104E. 9 of these 13 sera also showed
reduced binding to the triple mutant P42S/H103A/S104, while the other 4/13 bound
this triple mutant comparably strong as hMOG (also see 20.5). Thus, the triple mutant
revealed a further heterogeneity of sera recognizing the immunodominant P42. The triple
mutant also allowed to further diﬀerentiate those sera that recognize the second most
important epitope, the FG-loop. Within the subgroup of 17 sera with decreased binding
to H103A/S104E (patterns 2 and 6), four sera showed increased binding to P42S. The one
serum with pattern 6 recognition and a strongly increased P42S recognition showed poor
recognition of mMOG. This could be explained by other more subtle structural diﬀerences
between human and mMOG. In only 1 of these 4 sera, binding to the triple mutant was
decreased. The remaining 3 sera bound well to the triple mutant. One example is the
ON serum AEB048 that showed only 12% binding to H103A/S104E (pattern 2). This
serum recognized P42S very well (2057% binding to P42S and 1518% binding to mMOG,
compared to hMOG). In this case, binding to the triple mutant was not reduced, but was
also stronger than to hMOG (610%). Taken together, sera with decreased reactivity to
both P42S and to H103A/S104E also showed decreased reactivity to the triple mutant
P42S/H103A/S104E. 13 sera with increased reactivity to H103A/S104E did not recognize
P42S. In 9/13 cases, these autoantibodies did not recognize the triple mutant. Four sera
showed increased reactivity to the P42S mutant. In 3/4 sera, these autoantibodies also
bound the triple mutant well, although they did not recognize H103A/S104E.
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20.4 The N31D mutant
The no glycosylation mutant N31D did not signiﬁcantly lower anti-MOG recognition in
any of the sera. Examples of recognition of N31D are shown in ﬁgures 15, 20 and 22. This
proves that the glycosylated part of MOG is not recognized by autoantibodies. Instead,
8 sera recognized the unglycosylated MOG better than the hMOG (see 20.5). Five of
these patients showed low recognition of hMOG, with a FACS ratio below 2.0. Enhanced
recognition of the unglycosylated mutant was not linked to recognition of a certain epitope
pattern (3/8 recognized pattern 4, 2/8 pattern 1; 1/8 pattern 2; 1/8 pattern 7 and one
bound well to all mutants).
20.5 Higher reactivity to mutated variants of MOG
32/111 patients showed a clearly elevated (more than two fold) reactivity to mutated
variants of MOG as compared to hMOG. Some bound multiple mutants better than hMOG.
These 32 patients include 8 recognizing MOG better in the absence of glycosylation (N31D
mutant, details in 20.4). 12 patients recognized mMOG better than hMOG, 6 of these
also bound better to P42S than to hMOG. This increase in binding to P42S might be
explained by the rigidity of proline and the ﬂexibility of serine, allowing an induced ﬁt
of the protein to the antibody. For 6/12 patients with high reactivity to mMOG, no
epitope recognition pattern could be assigned; 3/12 showed pattern 2 recognition and
3/12 recognized other patterns. 17/111 patient sera bound H103A/S104E better than
hMOG, 4 of which also bound better to mMOG; 13 of these 17 sera recognized pattern 1
(reduced binding to P42S). 9/13 sera with increased binding to H103A/S104E and pattern
1 recognition (reduced binding to P42S) also showed reduced binding to the triple mutant
P42S/H103A/S104E, as described in 20.3. As explained in 20.2, these sera could contain
at least two diﬀerent kinds of anti-MOG antibodies- one recognizing the CC'-loop and one
other with improved binding to the artiﬁcial mutant H103A/S104E. However it seems that
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an antibody recognizes both loops simultaneously at the edge of the epitope. Another
possible explanation for increased recognition of MOG variants could be that high aﬃnity
anti-MOG antibodies do not recognize a MOG variant and hence allow lower aﬃnity anti-
MOG antibodies to bind. Theoretically, the sum of binding of these low-aﬃnity antibodies
could result in an increased FACS ratio. Taken together, a subset of 32/111 sera showed
increased reactivity to mutated variants of MOG. The most common mutants to elevate
autoantibody binding were H103A/S104E, mMOG and N31D.
20.5.1 The S104E mutation could mimic phosphorylated MOG
The glutamate mutation leads to a negative charge at this position, which is not present in
the wildtype variant of hMOG. This negative charge is reminiscent of phosphoserine. For
this reason, it was analyzed, using the phosphorylation prediction program NetPhos 2.O
[Blom et al. 1999], whether this particular serine residue is a likely site for phosphorylation.
With a score of 0.994, S104 is a very likely phosphorylation site (see ﬁgure 17).
20.6 Serial dilution of two sera showing diﬀerential recognition to
MOG variants
Sera of an adult ADEM patient 18078 and a pediatric TM patient (mono ADS) AEB-
123 were serially diluted in 1:4 steps up to a dilution of 1/12800. The adult ADEM
patient 18078 showed pattern 7 recognition with increased recognition to H103A/S104E
(as described in 20.5). As shown in ﬁgure 18, binding to hMOG was seen up to a dilution of
1/200, while binding to H103A/S104E was seen up to a dilution of 1/800. The decreased
recognition of P42S and mMOG is also seen at a dilution of 1/200. The pediatric TM
patient AEB-123 showed pattern 1 recognition. As shown in ﬁgure 18, the binding patterns
of this patient was seen up to a dilution of 1/3200. These results show that the binding
patterns are dose-independent.
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Figure 17: Prediction of phosphorylation sites using NetPhos 2.0 [Blom et al. 1999]. The serine
residue S104 is a very likely phosphorylation site with a score of 0.994.
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Figure 18: Serial dilution of two sera with diﬀerential recognition of MOG variants. The adult
ADEM serum 18078 showed enhanced recognition of the H103A/S104E mutant and did recognize
mMOG and the P42S mutant. Recognition of the R9G/H10Y mutant was reduced. This pattern
was seen at a dilution of 1/50 and 1/200. At a dilution of 1/800, only binding to the H103A/S104E
mutant was above the cut-oﬀ, reﬂecting the incresed recognition of this mutant. The pediatric
TM (mono ADS) serum AEB-123 did not recognize P42S/H103A/S104E, mMOG or P42S. This
pattern was seen up to a dilution of 1/3200. At a dilution of 1/12800, recognition of hMOG was
slightly below the cut-oﬀ.
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21 Comparison of MOG epitope analysis with mutated
variants versus competition with deﬁned mAbs
A commonly used method to analyze epitope recognition is competition with mAbs. This
technique has also been used to analyze the epitopes recognized by human anti-MOG an-
tibodies [McLaughlin et al. 2009, Proebstel et al. 2011]. The single amino acid mutation
assay was compared to blocking assays with deﬁned mAbs. The mAbs 8-18C5 and Y11
recognize diﬀerent epitopes on MOG [Breithaupt et al. 2008]. IgG binding of 15 sera in
competition with either 8-18C5 or Y11 was analyzed; both mAbs competed with the human
IgG in 15/15 sera. The tested sera recognized diﬀerent epitopes, 13 of them recognized
patterns 1, 2, 4, 5, 6 and 7 and two bound well to all mutants. Figure 19 shows two sera
that were blocked by the mAbs 8-18-C5 and Y11 to a similar extent, although they rec-
ognized diﬀerent epitopes as revealed by the MOG mutants; the mutation H103A/S104E
abrogated the binding of one, but did not interfere with the binding of the other serum.
This shows that mAbs can block binding of human anti-MOG IgG, even when a diﬀer-
ent epitope is recognized by the human antibodies. Hence, systematic mutation of amino
acids gives more detailed information about the epitopes recognized by human anti MOG
antibodies than competition assays with deﬁned mAbs.
22 MOG epitopes recognized by patients with diﬀerent
disease entities
A linkage between epitope recognition and diagnosis has been shown for antibodies against
heat shock proteins 60 and 65: patients with inﬂammatory bowel disease and coronary
heart disease and healthy controls each recognized diﬀerent epitopes [Fust et al. 2012]. For
this reason, it was assessed whether anti-MOG antibody epitopes also diﬀer between the
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Figure 19: Mutated variants of MOG allowed more precise insight into recognized epitopes
than blocking with mAbs. The two patient sera displayed here showed a diﬀerent reactivity
to mutated variants of MOG: ACJ-022 recognized the FG-loop containing H103/S104 and the
CC'-loop containing P42S (pattern 5); ACX053 did not bind the FG-loop, but recognized the
CC'-loop containing P42 (pattern 1). Nevertheless, both sera were blocked by the two anti-
MOG mAbs 8-18C5 and Y11 to a similar extent. The mAb 8-18C-5 recognizes the FG-loop of
MOG [Breithaupt et al. 2008]. Y11 binds cell-bound MOG and the hMOG peptide aa76-100
[Brehm et al. 1999].
analyzed patient groups. Distinct epitope patterns are recognized by anti-MOG antibodies
in the serum of patients with 6 diﬀerent clinical entities: ADEM, mono ADS, MS, CRION,
NMO and other relapsing ADS cases. Each epitope pattern was found in several clinical
presentations, as summarized in table 7. No statistically signiﬁcant association between
epitope recognition and diagnosis was found (Chi square test, p=0.27). Nevertheless, a
larger sample size might potentially reveal such an association. It is interesting to note
that in the CRION group, 4/10 and only 4/101 other patients showed more than 200%
binding to the N31D mutant. We analyzed whether patients with chronic inﬂammatory
diseases had an anti-MOG response directed against more epitopes than patients with a
monophasic disease. Out of 26 cases of chronic inﬂammatory diseases namely MS, NMO,
CRION and other relapsing ADS cases, 35% recognized multiple epitopes (patterns 5, 6 and
7) and 31% a single epitope (patterns 1, 2 and 3). Out of 85 patients with a monophasic
disease (ADEM and mono ADS), 27% recognized multiple epitopes (patterns 5-7) and
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44% recognized a single epitope (patterns 1-3). These results are summarized in table and
indicate that recognition of a single or of multiple epitopes is not linked to monophasic or
chronic disease.
Disease
No. of
patients
Pattern 1 Pattern 2 Pattern 3 Pattern 4 Pattern 5 Pattern 6 Pattern 7
No Epitope
Found
Mono ADS other
than ADEM
45 18 4 0 4 8 2 2 7
ADEM 40 16 5 1 5 5 3 3 2
MS 10 3 0 0 1 2 1 0 3
NMO like 2 0 0 0 0 1 1 0 0
CRION 10 3 1 0 4 0 0 1 1
Other relapsing
ADS
4 1 0 0 0 3 0 0 0
Table 7: Recognition of epitope patterns in diﬀerent disease groups
23 Long term analysis of individual epitope patterns on
MOG
In order to analyze the temporal stability of individual epitope patterns, follow-up sera of
11 anti-MOG antibody positive patients were analyzed with the diﬀerent MOG-constructs.
For 9/11 one of the above mentioned epitope patterns was assigned. The patterns stayed
constant in 9/9 analyzed cases for an observation period of up to 50 months (MS) with-
out evidence for intramolecular epitope spreading (ﬁgures 20 and 22). Constant epi-
tope patterns were found in MS, CRION and ADEM. This was especially remarkable
for MS patients. In pediatric MS patients, anti-MOG IgG persists with ﬂuctuations
[Proebstel et al. 2011]. For example, the anti-MOG reactivity of the MS patient ACJ-
162 (ﬁgure 22H) decreased below detection level after 12 months, but clear anti-MOG
reactivity was seen after 24 months. Here, the anti-MOG antibodies still recognized the
same pattern (pattern 1) after a follow-up period of 36 months. Diﬀerent epitope patterns,
1, 2, 4, 5, 6 and 7, stayed constant over years.
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Figure 20: Temporal stability of recognition of MOG-epitopes. Depicted is a case of pediatric MS
with a pattern 1 recognition. The recognition pattern stayed constant over the observation period
of 50 months. An increased recognition of hMOG after three months is marked with an asterisk.
24 Comparison of the dynamic of anti-MOG IgG with
anti-measles virus and anti-rubella virus IgG
Anti-MOG antibodies in patients with a monophasic disease course rapidly lose their anti-
MOG antibodies[Proebstel et al. 2011]. In order to assess, whether these patients are
generally incapable of producing a long-lasting IgG response, three patients with a rapid
decline of anti-MOG IgG were selected. All three patients had been vaccinated against
measles and rubella virus, IgG against these vaccines typically persist. All three patients
mounted a persisting IgG response against both measles and rubella virus, while they
rapidly lost the anti-MOG IgG (ﬁgure 21). This shows that the rapid loss of anti-MOG
IgG in these patients is not linked to a general incapability of producing a long-lasting IgG
response.
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Figure 21: Dynamic of anti-MOG IgG compared with antimeasles virus and antirubella virus
IgG. The IgG recognition of measles virus, rubella virus, and MOG was analyzed for an observation
period of up to 60 months. The response at disease onset was set as 100% for each antigen and the
subsequent responses were calculated. In these three patients, IgG against MOG declined quickly,
whereas the IgG response against measles and rubella virus vaccine was stable for the observation
period of 5 years. All three patients had a monophasic CNS inﬂammation. (A) Patient ACX-053
experienced a single episode of optic neuritis. (B and C) Patients ACJ-013 and ACJ-181 had
monophasic ADEM.
24 Comparison of the dynamic of anti-MOG IgG with anti-measles virus and
anti-rubella virus IgG 64
Figure 22: Temporal stability of recognition of MOG-epitopes. Ten sera were longitudinally
analyzed for their epitope recognition (additional to ﬁgure 20). The observation period was up to
37 months (I). The patients had diﬀerent diseases, namely ADEM (A-F), CRION (G) and MS (H-
J). Anti-MOG reactivity showed a second increase in all examined MS sera [Proebstel et al. 2011]
and the time point of the increase is labeled with a star (*). In the MS serum ACJ-162, the
anti-MOG IgG fell below the detection limit at 12 months (n.d., not detectable), but reappeared
at 24 months. Despite these ﬂuctuations in the intensity of anti-MOG reactivity, the epitope
recognition patterns stayed constant. The CRION patient experienced her 11th and 12th episode
of optic neuritis.
Part VI
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25 The polyclonal anti-MOG response is directed
against amino acid loops
In this work, 9 variants of MOG were expressed on the cell surface of HeLa cells with
an intracellular EGFP-tag. 111 sera with MOG antibodies, collected from patients with
diﬀerent inﬂammatory CNS diseases, were analyzed for the recognition of these mutants.
All epitopes identiﬁed in this work are located at loops that connect the β-strands of the
IgV-like fold of MOG. This observation is in harmony with the concept that antigenicity
correlates with solvent accessibility and ﬂexibility in proteins [Thornton et al. 1986]. It is
currently unknown whether the serum anti-MOG antibody response is polyclonal. This
work provides direct evidence for the polyclonality of at least a subgroup of anti-MOG sera,
because binding to multiple mutants was reduced in about a third of all donors. To further
analyze the clonality of these antibodies, isoelectric focusing, with subsequent Western
blotting of the puriﬁed anti-MOG antibodies could be performed, similar to Western blots
used for the analysis of oligoclonal bands.
26 Species speciﬁc recognition
Most of the patients recognizing hMOG did not recognize mMOG, largely because the
majority of sera did not bind to P42S, which is also found in mMOG. Other amino acid
diﬀerences between the two species also contribute to the diﬀerential recognition of human
and murine MOG (patterns 3, 4, and 7). The recognized proline at position 42 is also not
present in rats, not even in the New World primate Callithrix jacchus, but appears in the
rhesus monkey (Macaca mulatta). This species speciﬁc recognition pattern is diﬀerent from
the features of anti-AQP4 autoantibodies. Human anti-hAQP4 antibodies cross-react with
mAQP4; staining of mouse tissue was even used to identify NMO IgG [Lennon et al. 2004].
This study shows that other human autoantigens might be missed when screening with
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rodent tissue and even primate tissue might cause troubles.
27 Expanding the model of hMOG
Although human MOG has not been crystallized, crystal structures of mMOG
[Clements et al. 2003]and rMOG [Breithaupt et al. 2003] have been published. The overall
dimensions of the extracellular domain of MOG are 40 Ö 35 Ö 30 Å [Clements et al. 2003].
The observed maximum dimensions of Ab epitopes are 21Å x 28Å [Ramaraj et al. 2012].
As shown in ﬁgure 6, only 11 amino acids diﬀer between the extracellular domains of hu-
man and mMOG. Yet, the recognition of human anti-MOG IgG was dramatically reduced
to mMOG (see 26), with P42S having the strongest impact on antibody recognition. This
shows that this one diﬀerence between human and rodent MOG signiﬁcantly changes the
surface properties of MOG at this position, even though the Cα atoms are predicted to be
at the same positions, as shown in ﬁgure 23.
Figure 23: Sequence conservation of mMOG and hMOG mapped onto the three-dimensional
structure of mMOG. Selected residues are displayed in three diﬀerent sizes. Cα-atoms of residues
mutated in this study are shown as largest spheres: R9G/H10Y in red and blue, N31D greenish,
H103A/S104E in gray, and P42S and R86Q in purple. Cα-atoms of nonconserved residues, which
were not mutated in this study, are shown as midsized spheres: G59A/D60E, D74E/A75T, and
G77S. These Cα-atoms are displayed in blue, indicating conservative amino acid diﬀerences be-
tween mMOG and hMOG. Cα-atoms of nonconserved residues with side chains located inside the
protein are shown as small spheres: V20A and F96Y.
28 Pathogenicity of anti-MOG antibodies in humans 68
28 Pathogenicity of anti-MOG antibodies in humans
The pathogenic potential of human autoantibodies is best demonstrated by the trans-
fer of these antibodies into experimental animals as done with anti-AQP4 antibodies
[Bennett et al. 2009, Bradl et al. 2009, Saadoun et al. 2011, Kinoshita et al. 2009]. Hu-
man antibodies to MOG have all the characteristics of pathogenic autoantibodies: they
recognize MOG in its correct conformation, they are mostly of the complement ﬁxing
isotype IgG1 [Mader et al. 2011, Proebstel et al. 2011, McLaughlin et al. 2009], and they
activate antibody dependent cellular cytotoxicity [Mader et al. 2011, Brilot et al. 2009].
Their pathogenic activity, however, has not yet been shown with aﬃnity-puriﬁed anti-
bodies. Transfer experiments with concentrated human sera [Zhou et al. 2006] are dif-
ﬁcult to interpret, because human sera could have pathogenic compounds beyond anti-
MOG IgG. Only a minority of human sera with anti-MOG IgG are suitable for trans-
fer experiments in mice. The major autoantibody epitope found here is diﬀerent from
the immunodominant and pathogenic epitope in rodents [Breithaupt et al. 2008]. Human
anti-MOG antibodies mainly recognized the CC'-loop containing P42 of hMOG, whereas
most mouse mAbs to MOG recognized the FG- loop. Animal experiments have shown
that not all antibodies against MOG are pathogenic [Brehm et al. 1999, Marta et al. 2005,
Bï¾÷dingen et al. 2002]. Mouse mAbs, which recognize MOG on the cell surface and are
pathogenic, can recognize diﬀerent epitopes: both the mAb 8-18C5 and the mAb Y11
are pathogenic [Piddlesden et al. 1993]. Thus, one would expect that not only those hu-
man anti-MOG antibodies recognizing the FG-loop (patterns 2, 5, and 6), but that also
other antibodies recognizing another part of the surface of MOG, e.g., the CC'-loop, are
pathogenic. The CC'-loop is closer to the membrane than the FG-loop. Because this loop
is recognized by antibodies when displayed on the surface of transfected cells, it is most
likely also recognized on the surface of myelin. It is evident from features of the anti-MOG
mAb Y11 that the same Ab can recognize both a linear peptide and the cell- bound con-
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formationally intact MOG protein [Brehm et al. 1999]. Thus, it is likely that some of the
anti-MOG antibodies in patients recognizing cell- bound MOG also recognize linear pep-
tides. In the CNS, binding to a MOG peptide in solution, e.g. in the context of cell death,
will not cause complement ﬁxation, but might contribute to clearance by macrophages via
Fc-receptors.
29 Assay comparison and evaluation
This study shows that the application of mutant variants of MOG allows a more pre-
cise insight into epitope recognition than blocking with deﬁned mAbs does. In agreement
with previous studies, the anti-MOG mAb 8-18C5 competes with binding of human an-
tibodies to cell-bound MOG [McLaughlin et al. 2009, Proebstel et al. 2011]. This mAb
also inhibits sera recognizing diﬀerent epitopes. This is not surprising, because MOG is a
relatively small protein, with only 125 extracellular amino acids [Kroepﬂ et al. 1996]. At
the outermost periphery of the epitope, R52 of the 8-18C5 H chain contacts the MOG
amino acids Y40 and S45 [Breithaupt et al. 2003], making clashes with antibodies that
bind the nearby amino acid 42 to the center of their paratope highly likely. For this
reason, binding of a mAb can inhibit binding of anti-MOG autoantibodies, even if they
recognize diﬀerent distant loops of MOG. Therefore, speciﬁc mutation of single amino
acids gives a much more detailed and correct insight into epitope recognition, whereas
competition analysis might be misleading. Similar results were found for anti-acetylcholine
receptor (AChR) autoantibodies. Anti-AChR mAbs compete with human autoanti- bod-
ies [Tzartos et al. 1982]. Further epitope mapping revealed that some human anti-AChR
autoantibodies recognized diﬀerent epitopes than the competing mAbs; the area covered
by one single mAb was large enough to allow blocking of human autoantibodies recogniz-
ing distant epitopes [Luo et al. 2009]. This study analyzes epitopes of human anti-MOG
antibodies with mutated cell-bound MOG. Earlier studies using peptide ELISA assays
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[Xu et al. 2012, Haase et al. 2001, Khalil et al. 2006] would not give information on epi-
topes of conformationally intact MOG. This work shows that human anti-MOG antibodies
recognize the loops of structurally intact MOG, which should not be provided in a pep-
tide ELISA, and indeed two studies failed to identify these epitopes in an ELISA assay
[Xu et al. 2012, Haase et al. 2001]. Another study reported that linear epitopes aa 3748
and aa 4253 are immunodominant in a peptide ELISA assay, but these peptides were also
recognized by controls at a lower frequency [Khalil et al. 2006]. The donors assessed in
[Khalil et al. 2006] were adult MS patients, who rarely have IgG against conformationally
intact MOG. In addition, because a secondary antibody recognizing IgG, IgA, and IgM
was used in that study, it is likely that mainly low-aﬃnity IgM was detected.
30 Relevance of MOG-glyosylation on recognition by
human antibodies
To study the potential relevance of MOG-glycosylation in this study, the N31D mutant
[O'Connor et al. 2007] was used. This mutatiom completely abolished N-glycosylation of
MOG, indicating that in our MOG constructs N31 is the only used N-glycosylation site. A
second potential glycosylation site N52, which lacks the consensus N-glycosylation sequence
N-!P-[S|T], was found in mouse brain by tandem mass spectrometry [Zielinska et al. 2010].
This site was not considered a high-conﬁdence glycosylation site [Zielinska et al. 2010] and
it was not used to glycosylate MOG in HeLa cells in this study. In this study, ungly-
cosylated MOG was recognized well by all human anti-MOG antibodies, in agreement
with [O'Connor et al. 2007]. A subgroup of 8 in 111 sera even showed increased reactivity
to unglycosylated MOG, which might be due to the better accessibility of MOG lacking
the polycarbohydrate chain at its upper, very exposed edge of its extracellular domain.
This eﬀect is reminiscent of observations made in HIV, in which deglycosylation of the
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HIV envelope glycoprotein gp120 led to increased recognition by neutralizing antibodies
[Koch et al. 2003]. It will be of interest to analyze the glycosylation state of MOG in
healthy and patient brain.
31 Increased recognition of MOG mutant
H103A/S104E
In addition to unglycosylated MOG, other mutated variants of MOG were also recognized
at least twice as good as hMOG: 17 of 111 sera recognized H103A/S104E better, and 6
of 111 recognized P42S better than hMOG. Mutation of serine to glutamic acid, as in the
H103A/S104E mutant is used experimentally to mimic phosphorylation, a strategy called
pseudo-phosphorylation [Xiao et al. 2009]. It is possible that these antibodies are gen-
erated against phosphorylated MOG. NetPhos 2.0 [Blom et al. 1999] was used to predict
phosphorylation sites on hMOG and found S104 to be a likely site for phosphorylation, with
a score of 0.994. Further experiments are required to conﬁrm whether MOG in the human
CNS is indeed phosphorylated at S104 or other positions. Some post-translational modiﬁ-
cations have been shown to diﬀer in patient brain, e.g. about 25% of the MBP molecules
in healthy brain are citrullinated; this proportion can be up to 45% in MS patients and
even 70% in Marburg's disease [Lolli et al. 2006].
32 Temporal stability of epitope recognition
Although patients, in particular with ADEM, only show a transient IgG response to
MOG, others (in particular with MS) tend to have a persisting antibody response to
MOG [Di Pauli et al. 2011, Proebstel et al. 2011]. It was analyzed whether there was
intramolecular epitope spreading of anti-MOG antibodies. Interestingly, the recognized
epitopes remained constant. This was seen not only in patients with ADEM who rapidly
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lose their anti-MOG antibodies, but also in pediatric patients with MS and CRION who
have anti-MOG antibodies persisting for years. Hence, for MOG-antibodies there is nei-
ther intramolecular epitope spreading nor epitope loss. Autoantibody epitope spreading
has been reported for a number of autoimmune targets, among them anti-AChR antibod-
ies in myasthenia gravis [Vincent et al. 1994], anti-mitochondrial antibodies in primary
biliary cirrhosis [Mori et al. 2012], and anti-citrullinated protein antibodies in rheumatoid
arthritis [Sokolove et al. 2012]. Further experiments could analyze intermolecular epitope
spreading using puriﬁed anti-MOG antibodies to screen CNS proteins or other proteins for
cross-reactivity.
33 Stable IgG response upon vaccination in children
rapidly losing anti-MOG IgG response
The maintenance of serum IgG is crucial for our ability to ﬁght pathogens
[Amanna et al. 2007]. The persistence of serum IgG is based on long-lived plasma cells
that ﬁnd a survival niche in the bone marrow or inﬂamed tissue [Manz et al. 2005]. It was
of interest to examine whether those patients with a rapid decline of anti-MOG IgG were
still able to mount a persisting IgG response to other antigens. As expected, patients, who
rapidly lost their anti-MOG IgG, were still able to mount a persisting IgG response against
two pathogens: measles and rubella virus. This ﬁnding shows that these patients do not
have a general inability to generate long-lived plasma cells. Instead, it suggests that the
IgG secreting cells generated during their anti-MOG response are less competent to seed
the survival niches than are plasma cells generated after vaccination.
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34 Therapeutic consequences
The identiﬁcation of precise epitopes of autoantibodies can provide the basis for an antigen
speciﬁc depletion of relevant B cells. A proof of concept for such an antigen speciﬁc
therapy has recently been obtained in an animal model of diabetes [Henry et al. 2012].
This group used a mAb binding to insulin reactive B-cells to selectively deplete these. For
this approach, it is important to know the epitope recognized by the autoreactive B-cells,
as the applied mAb has to recognize a distinct epitope.
Many observations support the application of anti-CD20 treatment in NMO patients
with anti-AQP4 antibodies [Pellkofer et al. 2011]. In contrast, IFNβ is not a suitable
treatment for many NMO patients, since it may worsen the disease [Palace et al. 2010].
This might be due to the induction of the B-cell survival factor BAFF by IFNβ
[Krumbholz et al. 2008]. Up to now there are no reports about IFNβ treatment in anti-
MOG positive patients. It seems plausible that patients with anti-MOG antibodies rather
beneﬁt from plasma exchange or a B-cell-directed therapy. The rapid decline of anti-MOG
antibodies in ADEM patients [Proebstel et al. 2011] suggests that in these patients the an-
tibodies are derived from short-lived plasma cells. For this reason, a reduction of anti-MOG
antibodies after B-cell-directed therapy would be expected in these patients.
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